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Abstract
Early in the course of psychosis, alterations in brain connectivity accompany the emergence of psychiatric symptoms
and cognitive impairments, including processing speed. The clinical-staging model is a reﬁned form of diagnosis that
places the patient along a continuum of illness conditions, which allows stage-speciﬁc interventions with the potential
of improving patient care and outcome. This cross-sectional study investigates brain connectivity features that
characterize the clinical stages following a ﬁrst psychotic episode. Structural brain networks were derived from
diffusion-weighted MRI for 71 early-psychosis patients and 76 healthy controls. Patients were classiﬁed into stage II
(ﬁrst-episode), IIIa (incomplete remission), IIIb (one relapse), and IIIc (two or more relapses), according to the course of
the illness until the time of scanning. Brain connectivity measures and diffusion parameters (fractional anisotropy,
apparent diffusion coefﬁcient) were investigated using general linear models and sparse linear discriminant analysis
(sLDA), studying distinct subgroups of patients who were at speciﬁc stages of early psychosis. We found that brain
connectivity impairments were more severe in clinical stages following the ﬁrst-psychosis episode (stages IIIa, IIIb, IIIc)
than in ﬁrst-episode psychosis (stage II) patients. These alterations were spatially diffuse but converged on a set of
vulnerable regions, whose inter-connectivity selectively correlated with processing speed in patients and controls. The
sLDA suggested that relapsing-remitting (stages IIIb, IIIc) and non-remitting (stage IIIa) patients are characterized by
distinct dysconnectivity proﬁles. Our results indicate that neuroimaging markers of brain dysconnectivity in early
psychosis may reﬂect the heterogeneity of the illness and provide a connectomics signature of the clinical-staging
model.
Introduction
Psychotic disorders, including schizophrenia, are
characterized by heterogeneity in terms of etiopathol-
ogy, clinical presentation and outcome1. Although the
outcome after a ﬁrst episode of psychosis is better than
traditionally thought2, relapses within 5 years from the
initial episode are up to 80%3. Current deﬁnitions of
psychotic illnesses are mainly based on relatively short-
term evaluations and only poorly consider the long-
term, potentially progressive evolution of the illness.
Clinical staging, which has proven useful in somatic
medicine, is an alternative approach, which captures the
degree of disease progression in a given patient and
places the person along the continuum of the course of
illness1,4. Introduced to psychiatry by Fava and Kellner5,
clinical staging was developed and applied to psychotic
disorders by McGorry and collegues6–8. This approach
allows to distinguish earlier and more benign states
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from more chronic states, with the aim of selecting the
right treatment according to the clinical stage. As a
framework, it has proven to be useful in the imple-
mentation of early intervention in psychosis by distin-
guishing an ultra-high risk phase from ﬁrst-episode and
chronic phases. Mapping neurobiological markers,
such as brain imaging features, onto clinical stages
could further allow us to reﬁne the model and
validate the boundaries of the clinical groups, thus
broadening our understanding of psychotic disorder
pathophysiology9,10.
Abnormalities in white matter (WM) and structural
brain connectivity are well documented in schizo-
phrenia and have been related to the expression of
clinical symptoms, cognitive deﬁcits and differential
functional outcome11,12. For instance, WM micro-
structural properties assessed by diffusion-weighted
imaging (dMRI) are important in explaining deﬁcits in
the processing speed13–15, which is one of the most
impaired cognitive dimensions in ﬁrst-episode psychosis
and established illness16,17 and predicts the functional
outcome in patients18.
WM alterations are widespread in schizophrenia and
affect most of the cerebral lobes in chronic patients19–21.
From a whole-brain connectivity (or connectome) per-
spective, patients present a less efﬁcient brain-network
organization and a decentralization of core brain regions
and hubs12,21–24, which are important in maintaining
proper information integration underlying cognitive
functions in the brain25,26. Individuals in the early stages
of psychosis appear to have less consistent WM (as well as
grey matter (GM)) changes than chronic patients. This
observation has led to the hypothesis that there might be a
progression or a differentiation of brain connectivity
impairments across stages and over the course of the ill-
ness from prodromal symptoms to the ﬁrst-episode of
psychosis and, ﬁnally, to the relapsing and chronic pha-
ses10,27–30. Not all patients necessarily progress from one
stage to another, which adds complexity to the model.
Only a few studies have looked at the early phases after a
ﬁrst episode of psychosis31–34, or compared a ﬁrst episode
with multiple episodes27,35 or with non-remitting patients.
Indeed, there is a 5-year period following the ﬁrst psy-
chotic episode, called the ‘critical period' by Birchwood
and colleagues36, during which the most severe brain
changes appear to occur10.
The objective of the present work is to investigate brain
connectomes37,38 of early psychosis patients classiﬁed in
different stages (i.e., stage II, IIIa, IIIb, and IIIc) according
to their clinical proﬁles. Given the tight link between the
WM characteristics and the processing speed, we also
tested the relationship between the network properties
and the processing speed. Our cross-sectional analyses are
a ﬁrst step toward a neuroimaging investigation and
validation of the clinical staging model for psychosis
illness.
Materials and methods
Subjects
A total of 147 subjects (71 early-psychosis patients
(EPPs) and 76 healthy controls (HCs)) were included in
this cross-sectional study (Table 1). The 71 EPPs (49
males, 26.0 ± 6.2yo) were recruited from an early inter-
vention program (Treatment and Early Intervention in
Psychosis Program (TIPP)39) of the Lausanne University
Hospital, Switzerland. The entry criteria into the TIPP
were the following: between 18 and 35 years of age;
residence in the catchment area; and meeting the
threshold criteria for psychosis according to CAARMS
psychosis-threshold subscale40,41.
A total of 76 age, gender and handedness-matched HCs
(48 males, 26.7 ± 6.1yo) were recruited from the same
catchment area; they were not affected by any mood,
psychotic or substance-use disorder41 and had no ﬁrst-
degree relative with a psychotic disorder. A history of
neurological disorder, severe head trauma or mental
retardation (IQ < 70) were exclusion criteria for all
subjects.
All of the participants provided informed written con-
sent for this study, and the procedure was approved by the
Ethics Committee of Clinical Research of the Faculty of
Biology and Medicine, University of Lausanne,
Switzerland.
Clinical staging
The clinical stage was rated as the highest stage
achieved at the time of imaging42. The patients were
stratiﬁed into four distinct groups (stages II and IIIa-c
(Fig. 1)) based on a consensus assessment by two
experienced psychiatrists, according to the clinical-
staging model proposed by McGorry and colleagues7,42.
Any unclear issue was discussed with the case-managers.
The subjects in stage II were ﬁrst-episode psychosis
patients, with one psychotic episode according to the
CAARMS psychosis-threshold subscale40 and no past
episodes at the time of the study (i.e., discrete disorder).
Patients in stage III were deﬁned as follows: IIIa: incom-
plete remission from stage II at 12 months after entry to
care and following a reasonable course of treatment
(>3 months), with duration of illness no longer than 5
years; IIIb: recurrence or relapse of a psychotic episode
(i.e., discrete disorder has fully recovered but then
relapsed to the full extent described in stage II); IIIc: two
or more relapses after stage II with remission between
episodes. Further details on the patients’ assessment can
be found in SI.1.
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Other clinical and cognitive assessments
In patients, the symptoms severity was assessed with the
Positive and Negative Syndrome Scale (PANSS)43, and the
functioning level was assessed with the Global Assessment
of Functioning (GAF) scale44. For each patient, a consensus
diagnosis45 was realized by a senior psychiatrist and a senior
psychologist in charge of scale-based assessment over the
treatment period, based on DSM-IV criteria41. The levels of
cannabis and alcohol use were assessed with the Case
Manager Rating Scale (CMRS) and ranked as none, mild,
moderate, severe or extremely severe46. None of the
patients had extremely sever level of cannabis or alcohol
Table 1 Demographic and clinical characteristics of the investigated cohort
HC EPP II III IIIa IIIb IIIc p-value p-value p-value
n= 76 n= 71 n= 25 n= 46 n= 17 n= 17 n= 12 HC/EPP II/III IIIa/IIIb/IIIc
Age, years 26.8 (6.1) 26.0 (6.2) 23.5 (4.6) 27.3 (6.5) 26.0 (6.3) 26.6 (6.1) 30.2 (7.1) 0.43 0.012* 0.20
Gender, M/F 48/28 49/22 17/8 32/14 12/5 12/5 8/4 0.45 0.89 0.22
Handedness, R/L 66/10 64/7 25/0 39/7 14/3 15/2 10/2 0.53 0.040* 0.015*
Scanner upgrade, 63/13 46/25 15/10 31/15 10/7 12/5 9/3 0.012* 0.53 0.52
Trio/Prisma
GAF 83 (5) 59 (11) 58 (12) 59 (10) 55 (9) 63 (9) 60 (10) < 10–35* 0.67 0.073
Processing Speed 53 (9) 41 (12) 44 (13) 38 (11) 35 (10) 37 (15) 42 (6) < 10–8* 0.061 0.40
Diagnosis Sz/Sa/bP/
Sf/BP/MD/Pd
41 / 11 / 7 /
4 / 4 / 2 / 2
9 / 4 / 5 / 4
/ 2 / 1 / 0
32 / 7 / 2 / 0
/ 2 / 1 / 2
14 / 1 / 0 /
0 / 0 / 1 / 1
11 / 2 / 2 /
0 / 1 / 0 / 1
7 / 4 / 0 / 0
/ 1 / 0 / 0
– 0.020* 0.32
DOI, years – 3.0 (3.8) 0.8 (1.0) 4.2 (4.3) 1.9 (1.6) 4.0 (3.3) 7.4 (5.9) – 0.00028* < 10–6*
DUP, days – 438 (847) 107 (233) 665 (1029) 320 (545) 585 (963) 1282 (1433) – 0.016* 0.0029*
PANSS positive – 13 (4) 13 (5) 13 (4) 14 (4) 12 (4) 13 (5) – 0.98 0.51
PANSS negative – 15 (6) 15 (6) 15 (6) 17 (7) 13 (4) 16 (5) – 0.85 0.16
PANSS general – 33 (9) 35 (11) 32 (8) 35 (9) 30 (7) 30 (8) – 0.16 0.067
PANSS total – 61 (17) 63 (19) 60 (15) 66 (16) 55 (14) 58 (14) – 0.48 0.10
CPZ, mg/day – 409.2
(254.7),
12 unmd.
420.5
(218.5),
6 unmd.
403.6
(273.1),
6 unmd.
452.9
(324.2),
3 unmd.
367.9
(222.4),
1 unmd.
388.3
(282.8),
2 unmd.
– 0.67 0.90
CMRS drug N/M/O/S – 46 / 10 / 6
/0
18 / 6 / 1 /0 28 / 4 / 5 /0 13 / 2 / 2 /0 10 / 2 / 1 /0 5 / 0 / 2 /0 – 0.52 0.63
CMRS alcohol N/M/
O/S
– 22 / 37 / 1 /
2
7 / 16 / 1 /1 15 / 21 / 0
/1
7 / 9 / 0 / 1 6 / 7 / 0 / 0 2 / 5 / 0 / 0 – 0.50 0.76
Columns 2,3 report group-mean (standard deviation) values for the 76 healthy controls (HCs) and 71 early psychosis patients (EPPs) included in this study. Columns 4,5
detail the characteristics of two sub-groups of the EPPs’ cohort: stage II (ﬁrst episode psychosis patients) and stage III (more advanced early psychosis stages after the
ﬁrst psychotic event). Columns 6–8 detail the characteristics of a further subdivision of stage III patients: stage IIIa (non-remitting patients after stage II), stage IIIb
(relapse of a psychotic episode after stage II), stage IIIc (two or more relapses after stage II). Columns 9–11: p-values for statistical comparisons between HC/EPP, stages
II/III, stages IIIa/IIIb/IIIc groups (one-way ANOVA for continuous and interval variables and chi-square test for categorical variables; *p < 0.05).
Groups: HC (Healthy controls); EPP (Early Psychosis Patients)= stages II+ III; Stage III= stages IIIa+ IIIb+ IIIc
Gender: M males, F females
Handedness: R right-handed, L left-handed
Diagnosis: Sz schizophrenia, Sa schizo-affective disorder, bP brief psychotic disorder, Sf schizophreniform disorder, BP bipolar disorder, MD major depressive disorder
with psychotic features, Pd psychotic disorder not otherwise speciﬁed
DOI: Duration of Illness at the time of the study, deﬁned as the temporal lapse (years) between the crossing of psychosis threshold (according to CAARMS) and the
date of MR imaging.
DUP: Duration of Untreated Psychosis at the time of the study, deﬁned as the number of days between the psychosis onset and the date of entry in the TIPP program.
DUP information was not available for 12 out of 71 patients: values reported in the table refer to available data
PANSS: Positive, negative, general and total PANSS scores
CPZ: Chlorpromazine equivalent dose (mg/day); unmd.= unmedicated at the time of the study.
CMRS drug: Level of cannabis use, ranked as: none (N), mild (M), moderate (O), severe (S) according to CMRS scale. Data was not available for 9 out of 71 EPPs (4 stage-
IIIb and 5 stage-IIIc patients)
CMRS alcohol: Level of alcohol use, ranked as: none (N), mild (M), moderate (O), severe (S) according to CMRS scale. Data was not available for 9 out of 71 EPPs (4
stage-IIIb and 5 stage-IIIc patients)
Griffa et al. Translational Psychiatry            (2019) 9:62 Page 3 of 10
use. Antipsychotic doses were converted to chlorpromazine
equivalents47,48. All of the subjects were assessed with the
MATRICS Consensus Cognitive Battery49,50.
MRI measurements and connectome reconstruction
Each subject underwent an MR-imaging session on a 3-
Tesla Siemens scanner, including magnetization-prepared
rapid acquisition gradient echo (MPRAGE) sequence (1-
mm in-plane resolution, 1.2-mm slice thickness) and
diffusion spectrum imaging (DSI) sequences (257
diffusion-weighted volumes and 1 b0 volume, maximum
b-value 8000 s/mm2, 2.2 × 2.2 × 3mm3 resolution). Dur-
ing the study, there was a routine MRI-system upgrade
from the MAGNETOM-Trio to the MAGNETOM-
Prisma Siemens system. Imaging parameters were pre-
cisely matched before and after the upgrade, and the same
32-channel head coil was used.
Individual connectomes were estimated by combining
MPRAGE and DSI data51. Brieﬂy, MPRAGE volumes
were segmented into WM, GM and cerebrospinal ﬂuid
compartments. The GM was parcellated into 82 (68
cortical and 14 subcortical) regions based on the Desikan-
Killiany atlas52. Reconstructed DSI-data were used to
compute generalized fractional anisotropy (gFA)53 and
apparent diffusion coefﬁcient (ADC)23 scalar maps, and
for deterministic streamline tractography. The structural
connectivity between each pair of cortical and subcortical
regions was quantiﬁed as the number of streamlines
connecting the two regions, which resulted in 82-nodes,
weighted undirected brain-networks. For consistency
reasons and to limit possible biases in the network ana-
lyses54,55, connections that were present in less than 50%
of the subjects were discarded.
Further details regarding MRI acquisitions’ parameters,
data processing and connectome reconstruction can be
found in the SI.2, SI.3.
Brain connectivity measures
Global and nodal (i.e., speciﬁc to single brain regions)
connectivity measures were considered. The overall brain
network strength was quantiﬁed as the total streamline
count in the network. The centrality of each brain region
in the network was quantiﬁed with the nodal strength,
which was deﬁned as the weighted sum of the node’s
connections. Tract-average gFA53 and ADC values were
computed for each connection of individual brain net-
works. gFA and ADC values relate to organizational
and microstructural properties of the WM, including
myelination levels, axonal packing and ﬁbre coherence56.
The network efﬁciency and clustering coefﬁcient57
were investigated in supplementary analyses (SI.8,
Figure S4−S5).
Statistical methods
Statistical differences between the subjects’ groups were
assessed with multi-factor ANCOVA within a general
linear model (GLM) framework. Age, gender, handedness
and a ‘scanner-upgrade’ variable were added as co-variates
in all of the analyses. Global network analyses were
repeated on data acquired on the MAGNETOM-Trio or
on the MAGNETOM-Prisma system only to further
exclude major effects of the scanner upgrade on the
results. The effect size was quantiﬁed with the Cohen’s d
coefﬁcient58 between GLM residual distributions, after
correcting for covariates. Continuous variables’ cross-
group progression was tested with the Jonckheere-
Terpstra (JT) test for ordered alternative hypotheses59.
The false discovery rate correction for multiple compar-
isons was applied when indicated60. Logistic regression
was used to assess the cognitive impairments (MATRICS
scores) of patients with respect to healthy controls (see
SI.4). Relationships between neuroimaging and clinical/
cognitive variables were assessed with Pearson’s correla-
tion coefﬁcient (r). A sparse linear discriminant analysis
(sLDA)61,62 on nodal strength values was performed on
patients only to investigate whether distinct brain con-
nectivity features can be associated with distinct clinical
stages. Leave-one-out cross validation (LOOCV) error
and inter-class distances in the sLDA feature space were
used as indicators of classes’ separability. In these ana-
lyses, sLDA was meant to explore the neuroimaging
patterns characterizing the different early-psychosis
stages, and not to generalize to a prediction setting. For
further details see SI.5, Figure S1.
Results
Subjects and clinical staging
We investigated the brain connectivity alterations that
occur in young adults in the early phases of psychosis
(EPPs), classiﬁed into stages II, IIIa, IIIb and IIIc, and in
comparison with healthy controls (HCs). The
Fig. 1 Schematic representation of the clinical staging model
(7,41). Stage I: early or late prodromal patients with mild or sub-
threshold symptoms; Stage II: ﬁrst-episode of psychosis (i.e., ‘discrete
disorder’); Stage IIIa: incomplete remission; Stage IIIb: one relapse;
Stage IIIc: multiple relapses; Stage IV: chronic outcome with severe,
persistent illness. This study included patients classiﬁed in stages II, IIIa,
IIIb or IIIc
Griffa et al. Translational Psychiatry            (2019) 9:62 Page 4 of 10
demographics of the patients and controls, the cognitive
and clinical scores, and the related statistical comparisons
are reported in Table 1. The patients classiﬁed into stage
II had signiﬁcantly shorter duration of illness and dura-
tion of untreated psychosis compared to stage III
(including, as a whole, stages IIIa, IIIb and IIIc), and there
was a signiﬁcant effect of both duration of illness and
duration of untreated psychosis across stages IIIa-IIIb-
IIIc. We note that the inter-group differences in duration
of illness are implicit to the clinical-staging deﬁnition.
In patients, there were no inter-group differences in the
GAF, processing speed, PANSS scores, CMRS levels or
medication dose (CPZ equivalents) as assessed at the time
of MR-imaging. The EPPs had lower GAF and processing
speed scores compared to the HCs.
There were no signiﬁcant differences in the age, gender
or handedness between the EPPs and HCs. Stage-II
patients were on average younger than stage-III patients,
while no age-difference was present among the different
sub-groups of the stage-III patients. There was an unba-
lance in the proportion of right-handed subjects across
the patient sub-groups.
Brain connectivity impairments in stage II and stage III
patients
When considering the totality of the EPPs, irrespectively
of their classiﬁcation into clinical stages, we found
reduced overall connectivity strength in EPPs compared
to HCs (p= 0.00086, d= 0.55), and trend-level alterations
of the whole-brain tract-average gFA (p= 0.051, d= 0.32)
and ADC (p= 0.068, d= 0.30) values (Figure S2). Using
JT-analysis for ordered alternative hypotheses, we found a
signiﬁcant progressive decrease in the brain network
connectivity strength (JTp= 0.00027) and average gFA
(JTp= 0.038), with connectivity measures higher in HCs,
intermediate in stage-II patients and lower in stage-III
patients. The tract-average ADC progressively increased
across groups (JTp= 0.0070). Post-hoc ANCOVA
revealed a signiﬁcant impairment in the connectivity
measures in stage-III patients compared to HCs (overall
connectivity strength: p= 0.00085, d= 0.63; average gFA:
p= 0.038, d= 0.39; average ADC: p= 0.021, d=−0.42)
(Fig. 2). There was a trend of decreased connectivity
strength in stage-II patients compared to HCs (p= 0.074,
d= 0.41). No signiﬁcant pair-wise differences were found
between stage-II patients and HCs for the other con-
nectivity measures or between stage-II and stage-III
patients. Consistent results were found when analyzing
only data acquired before or after the MRI scanner
upgrade, or when including right-handed subjects only
(for related analyses, see SI.6, SI.7 Table S1-S2, Figure S3).
For supplementary analyses with additional network
measures, see SI.8 and Figure S4−S5.
Identiﬁcation of vulnerable brain regions
Considering that the largest whole-brain effect was
observed for the overall network strength, we performed a
local JT-analysis for ordered nodal connectivity-strength
impairments {HC ≥ stage II ≥ stage III} to identify the
brain regions that contribute the most to the global effect.
A total of 22 out of 82 brain regions demonstrated a
signiﬁcant cross-group progressive decrease in the nodal
strength (JT-test, uncorrected p < 0.05) (Fig. 3a). Vulner-
able regions included the superior frontal gyri, precunei
and lateral fronto-basal, somato-motor and temporo-
mesial cortices in both hemispheres; the left thalamus,
superior-parietal cortex and Heschl’s gyrus; and the right
caudate, pallidum and lateral-occipital cortex (Table S3).
A total of 2 out of 22 regions (left pars opercularis and left
superior-parietal) remained signiﬁcant after multiple
Fig. 2 Brain connectivity measures are impaired in stage II and stage III patients. Scatter-plots of overall brain connectivity strength and whole-
brain tract-average gFA and ADC for healthy controls (HC), stage II and stage III patients. Residuals after correction for age, gender, handedness and
scanner-upgrade are reported. For single-group scatter-plots, the standard error of the mean (light blue area) and the group standard deviation (grey
area) around the group mean (black line) are reported. Grey dotted lines indicate the average values of the HC group; blue lines with asterisk
represent statistically signiﬁcant group-differences (uncorrected p < 0.05); grey lines represent trend-level differences (uncorrected p < 0.1). JT p-
values for ordered alternative hypotheses testing ({HC ≥ stage II ≥ stage III} for connectivity strength and gFA, {HC ≤ stage II ≤ stage III} for ADC) are
reported
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comparison correction (FDR < 0.05). A majority of vul-
nerable regions ranked among the most central nodes
(hubs and rich club) of the brain network (SI.9, Table S3).
A comparable set of vulnerable regions was identiﬁed
when considering only subjects scanned before the MRI
system upgrade, or when considering right-handed sub-
jects (SI.6, SI.7, Figure S6).
Characterization of stage III patients
To explore the heterogeneity of brain connectivity
alterations across psychosis stages II/IIIa/IIIb/IIIc, which
are possibly associated with different temporal and/or
clinical pathways of pathological evolution, we performed
an sLDA on the nodal strength values. SLDA is a multi-
variate technique that identiﬁes directions (linear dis-
criminant directions, LDDs, Figure S7) in the space of the
nodal strength values, which maximize the inter-class
separation61,62. The leave-one-out cross-validation
(LOOCV) error of the sLDA classiﬁcation for stages II/
IIIa/IIIb/IIIc was 0.60 (below chance-level LOOCV-error=
0.75 and naïve-classiﬁer LOOCV-error= 0.65, see SI.5
for further details), suggesting that the different clinical
stages are characterized by distinct nodal connectivity
patterns. Figure 4a shows the spatial organization of the
patients in the sLDA feature space. We note that, in the
sLDA feature space, there was no obvious pattern in the
distribution of the subjects with respect to the scanner
upgrade or to the subjects’ handedness, indicating that
these two factors are not major drivers of data classiﬁ-
cation (Figure S8-S9). When considering the inter-class
distances in the sLDA feature space, non-remitting
patients (stage IIIa) formed the most separable class
(Fig. 4b). On the other hand, the remitting patients with
multiple relapses (stage IIIc) formed the less separable
class, and the minimum inter-class distance was observed
between the two remitting groups (stages IIIb and IIIc).
When performing the cross-validation procedure, the
majority of stage IIIc patients were (mis)classiﬁed in the
class IIIb (Fig. 4c), suggesting an overlapping dyscon-
nectivity signature between stages IIIb and IIIc.
Relationship with clinical and cognitive proﬁles
Among the MATRICS domains, the processing speed
was the most impaired in the patients (including all
stages) compared to the controls (logistic regression
analysis, SI.4). There was a signiﬁcant positive correlation
between the processing speed and the overall network
strength in both HCs (r= 0.26, p= 0.024) and EPPs (r=
0.26, p= 0.049). This correlation was driven by the con-
nectivity strength between the 22 vulnerable regions
(HCs: r= 0.40, p= 0.00044; EPPs: r= 0.33, p= 0.012)
(Fig. 3b), and no relationship was found between the
processing speed and the connectivity strength in the
remainder of the network. In patients, we investigated the
subjects’ scores along the three discriminant directions
(LDDs) identiﬁed in the sLDA. The ﬁrst and third-LDD
patients’ scores correlated with the duration of illness
(respectively, r=−0.30, p= 0.00075 and r=−0.38, p=
0.0011); the ﬁrst-LDD scores correlated with the proces-
sing speed (r= 0.28, p= 0.037). We did not ﬁnd any
relationship between the connectivity measures (overall
network and vulnerable regions connectivity strength,
average gFA, average ADC) and the duration of illness,
duration of untreated psychosis, PANSS scores, GAF
scores, CMRS levels and medication dose in patients.
Discussion
White-matter alterations that occur in the early stages
of psychosis may parallel the course of the illness and
differentiate the clinical subtypes9,10,63. In this cross-
sectional work, we investigated the white-matter con-
nectivity of early-psychosis patients (EPPs) in different
Fig. 3 Connectivity strength between vulnerable brain regions selectively correlates with processing speed. a Cortical surface plot of nodal
JT p-values for ordered impairment of nodal strength values {HC ≥ stage II ≥ stage III} (uncorrected p < 0.05; cortical regions with uncorrected p ≥ 0.05
are coloured in grey). b Relationship between: brain connectivity strength between vulnerable grey matter regions, and processing speed, in HCs
(blue dots, r= 0.40, p= 0.00044) and EPPs (red dots, r= 0.33, p= 0.012) (*p < 0.05). Grey lines: linear least squares ﬁtting
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clinical stages after the ﬁrst psychotic episode and in
comparison with healthy controls (HCs). We found that
the EPPs have reduced brain connectivity strength, lower
gFA and higher ADC values compared to the HCs. Such
connectivity impairments are more severe in the advanced
(early) stages than in the ﬁrst-episode of psychosis (stage
II), and they converge on a set of vulnerable brain regions
whose connectivity strength selectively correlates with the
processing speed. Finally, using a linear discriminant
analysis technique, we showed that clinical subtypes are
characterized by distinct brain-connectivity proﬁles.
Our results on brain connectivity alterations across
early-psychosis stages complement recent studies that
indicate progressive brain tissue atrophy across clinical
stages10,26, and progressive dysconnectivity from recent-
onset to chronic schizophrenia patients32,64. While our
data, being cross-sectional, cannot directly conﬁrm a
progressive change of WM-connectivity over the early
course of the pathology, they reveal an association
between WM-connectivity alterations and clinical stages.
These alterations are spatially diffuse in the brain, but
they converge on a vulnerable subnetwork that spans
frontal, inter-hemispheric, cortico-thalamic and striatal
circuits. This vulnerable subnetwork spatially aligns with
the literature on WM-impairments in
schizophrenia12,21,22,65 and partially overlaps (~40%) the
brain’s ‘affected-core’ that we detected in previous work
on chronic patients23. Within the subnetwork, the most
signiﬁcant effects were found in the left hemisphere, in
the superior parietal and frontal cortices (which suggests
an involvement of the superior longitudinal fasciculus,
previously associated with a high risk for developing
psychosis29) and in the pars opercularis of the inferior
frontal gyrus (a language area that, together with the
Heschle’s gyrus, has been related to auditory hallucina-
tions66–68). The vulnerable subnetwork includes the main
brain-network hubs (namely, the superior frontal and
superior parietal cortices, precuneus, insula and thala-
mus), which are consistently implicated in schizophrenia
pathophysiology21,22 and whose early impairment might
relate to genetic and clinical risk factors69–71. Our ﬁndings
corroborate the dysconnectivity hypothesis of schizo-
phrenia pathophysiology and suggest that the early
decentralization of vulnerable brain regions, including
hubs, might play a role in the aetiology of the disorder.
The connectivity strength between vulnerable brain
regions selectively correlates with the processing speed, in
both patients and controls, which indicates an involve-
ment of these regions and connections in maintaining fast
response and proper information integration in the brain.
Fig. 4 Early psychosis clinical stages are characterized by distinct brain regions’ connectivity proﬁles. a Patients’ representation in the sLDA
feature space when sLDA is performed on all the available EPPs. sLDA projects patients’ data (nodal connectivity strength values) onto a three-
dimensional feature space where the inter-class separability is maximized. In the plots, each axis represents one of the three linear discriminant
directions (LDDs) deﬁning the sLDA feature space, and each point represents a single patient colour-coded according to his/her clinical-staging
condition. Dotted lines represent 2-standard deviation intervals for each class. b Inter-class Euclidean distance matrix, with distances computed
between class centroids in the sLDA feature space. On the right: bar plot representing the average distance of each clinical staging class with respect
to the other three groups. c Confusion matrix from LOOCV indicating the percentage of subjects (i.e., the number of subjects relative to their true
class size) classiﬁed in each class. Rows: true classes; columns: LOOCV predicted classes
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The processing speed is a core dimension of the cognitive
deﬁcit that is observed not only in chronic schizo-
phrenia13,14 but also in ﬁrst-episode and clinical high-risk
populations17,72,73, and it could mediate working memory
impairments15. In our sample, the processing speed was
impaired in EPPs compared to HCs, with a statistical
effect that exceeded that of other cognitive domains. Our
results suggest that inter-subject WM variability in con-
nections vulnerable to psychosis could mediate inter-
subject variations in the processing speed.
To assess the connectivity strength and microstructural
properties of WM tracts in patients and controls, we
investigated the number of streamlines (NOS), average
gFA and average ADC values. These measures indirectly
relate to the tract volume and to tissue microstructural
properties such as local axonal packing, membrane per-
meability and myelin properties56,74. Alterations in NOS,
gFA and ADC are compatible with neurobiological pro-
cesses that have been associated with schizophrenia, such
as neuroinﬂammation, myelin impairment and loss of
tissue volume75–77. It has been suggested that oxidative
stress is an important risk factor for developing schizo-
phrenia. Redox dysregulation interacts with neuroin-
ﬂammation and glutamatergic hypofunction to impair
oligodendrocyte maturation and myelination78–80. In early
psychosis, WM gFA values relate to brain concentrations
of glutathione, a fundamental antioxidant that prevents
oxidative stress and oligodendrocytes sufferance78. Ele-
vated ADC values have been directly associated with
demyelination processes in animal models with myelin
deﬁciency81, and both gFA and ADC impairments in
schizophrenia have been related to deﬁcits in the density
or myelination of axonal ﬁbers82. In schizophrenia, NOS-
connectivity relates to cytoarchitectonic abnormalities of
pyramidal neurons, which are centrally implicated in the
disorder83. In this study, we found that NOS-connectivity
bears the largest effect for progressive connectivity
changes across psychosis stages. While this result suggests
that NOS might be sensitive to pathological processes that
occur early and persist over the development of the dis-
ease, this measure remains an unspeciﬁc marker of WM-
organization. Future studies that employ additional
dMRI-techniques for WM microstructural assess-
ment84,85 could better characterize the neurobiological
processes that underlie macro-scale connectivity altera-
tions across psychosis stages.
Although our analyses suggest a progressive WM-
connectivity impairment from the ﬁrst episode to more
advanced (early) psychosis stages, we did not ﬁnd in the
ﬁrst instance direct correlations between neuroimaging
markers and duration of illness. A possible explanation for
this ﬁnding is that connectivity alterations follow spatially
non-homogeneous and temporally non-linear patterns
over the course of the pathology, with periods of faster
and slower WM changes localized in different areas of the
brain32,34. A second complementary explanation is that
different clinical subtypes can experience different spatio-
temporal patterns of WM alteration. For example, it is
plausible that an early-psychosis patient with a non-
remitting course of illness could present a different or
more severe dysconnectivity pattern than a relapsing-
remitting patient, with duration of illness being equal. A
large longitudinal study on ﬁrst-episode schizophrenia
found that individuals with extended periods of relapse
had more severe brain-tissue atrophy compared to brief-
or no-relapse conditions86, while GM-volume alterations
measured at the time of the ﬁrst psychotic episode par-
tially predicted the course of psychosis into continuous or
remitting illness34. Moreover, WM-changes detected after
a ﬁrst psychotic episode can partially reverse with the
remission of acute psychotic symptoms87.
To investigate whether different early-psychosis clinical
subtypes are associated with distinct WM-connectivity
patterns, we performed an exploratory sparse linear dis-
criminant analysis (sLDA) on nodal connectivity-strength
values. Our analysis suggests that distinct brain con-
nectivity features characterize the clinical stages and
identiﬁes axes of pathological evolution in terms of both
(cross-sectional) temporal progression (qualitatively, 1st
and 3rd LDDs (Fig. 4a), with patients’ scores along these
dimensions correlating with the duration of illness) and
clinical differentiation in terms of relapsing-remitting or
non-remitting pathology (2nd LDD, Fig. 4a).
It should be noted that additional factors that were not
accounted for in our analyses, such as diagnostic hetero-
geneity, number of relapses and differential longitudinal
follow-up, could blur the boundaries of the clinical groups
(stages II, IIIa, IIIb, and IIIc) and the corresponding neu-
roimaging markers. Our data are cross-sectional and it is
not possible to foresee the pathological evolution of single
individuals. In addition, our sample-size is relatively small,
which limits the statistical power and the generalizability
of our exploratory sLDA analysis to a classiﬁcation or
predictive setting. Finally, although no relationship was
found between brain-connectivity measures and anti-
psychotic dose, and no differences in CPZ equivalents
were found between patient subgroups, possible iatrogenic
or other secondary effects on the reported neuroimaging
measures cannot be completely excluded. While some
studies have shown that medication can negatively impact
WM connectivity88,89, others found no effect90, and this
aspect should be further assessed in future research.
In conclusion, our work shows that neuroimaging
markers of brain dysconnectivity and core-network
decentralization are more severe in more advanced
early-psychosis stages and typify relapsing-remitting and
non-remitting clinical proﬁles, thus providing a con-
nectomics perspective of the clinical-staging model. Based
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on these results, we expect that the investigation of large
datasets (including stage-I and stage-IV individuals), the
inclusion of additional clinical, neurobiological and mul-
timodal brain-connectivity features, and longitudinal
designs combined with machine learning approaches will
signiﬁcantly contribute to model and understand the
unfolding of psychosis-spectrum disorders across clinical
stages.
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